VanEck Pharmaceutical ETF
PPH
48 hedge funds and large institutions have $136M invested in VanEck Pharmaceutical ETF in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 5 closing their positions.
92% more capital invested
Capital invested by funds: $71M → $136M (+$65.2M)
31.01% more ownership
Funds ownership: 24.58% → 55.6% (+31%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
4% less funds holding
Funds holding: 50 → 48 (-2)
30% less call options, than puts
Call options by funds: $312K | Put options by funds: $445K
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$65.3M |
| 2 |
SG Americas Securities
New York
|
+$5.68M |
| 3 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$1.25M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$848K |
| 5 |
WI
Wintrust Investments
Chicago,
Illinois
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$2.43M |
| 2 |
SCM
Stuyvesant Capital Management
Armonk,
New York
|
-$1.62M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$915K |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
-$696K |
| 5 |
VF
Virtu Financial
New York
|
-$572K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Creative Planning
Overland Park,
Kansas
| – | -$139K | -2,360 | Closed |
|
|
WEC
52
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$5.91K | -100 | Closed |
|
PPH Hedge Fund Activity: Q3 2017 in Review
48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2017, worth a combined $136M — up 92% from $71M a quarter earlier.
Fund positioning in PPH was balanced in Q3 2017: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 17 trimmed.
The largest buyer was Bank of America, adding an estimated $65.3M. The largest seller was Raymond James Financial Services Advisors, cutting an estimated $2.43M.
- 48 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2017, down from 50 in Q2 2017.
- Funds reported $136M of VanEck Pharmaceutical ETF stock for Q3 2017, up 92% quarter-over-quarter.
- 5 funds opened new VanEck Pharmaceutical ETF positions in Q3 2017 and 5 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2017 was Bank of America, an estimated $65.3M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2017 was Raymond James Financial Services Advisors, an estimated $2.43M sold.
Based on aggregated 13F filings for Q3 2017.